Physiomics PLC Renewal of Agreement with Merck (5858K)
17 Diciembre 2018 - 1:00AM
UK Regulatory
TIDMPYC
RNS Number : 5858K
Physiomics PLC
17 December 2018
Physiomics plc
("Physiomics") or ("the Company")
Renewal of Agreement with Merck
Physiomics plc (Oxford, UK) is pleased to announce that,
following a successful collaboration this year and pursuant to the
Master Services Agreement signed with Merck, a leading science and
technology company, in November 2017, it has agreed with its client
a program of work for the next calendar year. Physiomics and Merck
have entered into contracts with a total value of GBP435,000 for
projects that are envisaged to be completed during calendar 2019,
and which will span a range of drug targets and treatment types in
both pre-clinical and clinical settings.
In its 2018 program of work with Merck, Physiomics believes it
has developed genuinely ground-breaking predictive models that will
add significant value to drug development programmes. The two
companies have provisionally agreed that they will aim to publish
selected elements of their work at one or more major conferences in
2019.
Dr Jim Millen, CEO of Physiomics, said: "We are now entering the
eighth year of our relationship with Merck, during which time we
have provided a range of pre-clinical and clinical predictive
modelling services using our Virtual Tumour technology. We remain
immensely proud to be working with one of the world's foremost
pharmaceutical companies, in an area as important and rapidly
growing as oncology. We look forward to this collaboration
continuing."
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
WH Ireland Limited (nomad)
Katy Mitchell
+44 (0) 161 832 2174
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
About Physiomics
Physiomics plc (AIM: PYC) is a solutions provider to the R&D
based pharmaceutical and biotechnology industry with a focus on
oncology. The Company's Virtual Tumour technology uses computer
modelling to predict the effects of cancer drugs and treatments to
improve the success rate of drug discovery and development projects
while reducing time and cost. The predictive capability of Virtual
Tumour has been confirmed by 55 projects, involving over 25 targets
and 60 drugs, and has worked with clients such as Merck KGaA, Merck
& Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics senior management has academic and commercial
expertise, including over 90 years collectively of working in
oncology and/or computational biology and over 100 publications in
peer reviewed journals.
For more information please visit:
www.physiomics-plc.com
www.twitter.com/Physiomics
www.linkedin.com/company/physiomics-plc/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRQZLFFVLFLFBL
(END) Dow Jones Newswires
December 17, 2018 02:00 ET (07:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024